Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)

2008

2074 Background: The survival for patients with recurrent GBM is dismal, with grade 3 hematologic toxicity, and no CNS hemo...

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

0

References

13

Citations